These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 27083788)

  • 1. Hyaluronic acid based hydroxamate and conjugates with biologically active amines: In vitro effect on matrix metalloproteinase-2.
    Ponedel'kina IY; Gaskarova AR; Khaybrakhmanova EA; Lukina ES; Odinokov VN
    Carbohydr Polym; 2016 Jun; 144():17-24. PubMed ID: 27083788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
    Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
    Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
    Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
    Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
    Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.
    Hugenberg V; Breyholz HJ; Riemann B; Hermann S; Schober O; Schäfers M; Gangadharmath U; Mocharla V; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
    J Med Chem; 2012 May; 55(10):4714-27. PubMed ID: 22540974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First insight into structure-activity relationships of selective meprin β inhibitors.
    Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors.
    Nuti E; Cuffaro D; D'Andrea F; Rosalia L; Tepshi L; Fabbi M; Carbotti G; Ferrini S; Santamaria S; Camodeca C; Ciccone L; Orlandini E; Nencetti S; Stura EA; Dive V; Rossello A
    ChemMedChem; 2016 Aug; 11(15):1626-37. PubMed ID: 27356908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carborane-Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron-Capture Therapy (BNCT).
    Lutz MR; Flieger S; Colorina A; Wozny J; Hosmane NS; Becker DP
    ChemMedChem; 2020 Oct; 15(20):1897-1908. PubMed ID: 32720425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.
    Krumme D; Tschesche H
    Bioorg Med Chem Lett; 2002 Mar; 12(6):933-6. PubMed ID: 11958997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.
    Subramaniam R; Haldar MK; Tobwala S; Ganguly B; Srivastava DK; Mallik S
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3333-7. PubMed ID: 18442906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2.
    Zhang W; Hou TJ; Qiao XB; Huai S; Xu XJ
    J Mol Model; 2004 Apr; 10(2):112-20. PubMed ID: 14986176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium hyaluronate-g-2-((N-(6-aminohexyl)-4-methoxyphenyl)sulfonamido)-N-hydroxyacetamide with enhanced affinity towards MMP12 catalytic domain to be used as visco-supplement with increased degradation resistance.
    Leone G; Pepi S; Consumi M; Lamponi S; Fragai M; Martinucci M; Baldoneschi V; Francesconi O; Nativi C; Magnani A
    Carbohydr Polym; 2021 Nov; 271():118452. PubMed ID: 34364546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M; Tordai H; Trexler M; Bányai L; Patthy L
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome.
    Mori M; De Lorenzo E; Torre E; Fragai M; Nativi C; Luchinat C; Arcangeli A
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):289-95. PubMed ID: 22520332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.
    Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G
    Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugates of modified hyaluronic acid with amino compounds for biomedical applications.
    Buffa R; Odstrčilová L; Šedová P; Basarabová I; Novotný J; Velebný V
    Carbohydr Polym; 2018 Jun; 189():273-279. PubMed ID: 29580409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.